Logo

Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

Share this

Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

Shots:

  • Leo Pharma to get exclusive rights to develop & commercialize brodalumab in Australia- Brazil- Egypt- Mexico- Russia and Saudi Arabia for the treatment of moderate-to-severe psoriasis
  • The sub-licensing agreement complements the ongoing licensing agreement b/w Leo & AstraZeneca to develop & commercialize brodalumab in Europe. Bausch Health has the rights to commercialize brodalumab through a licensing agreement with AstraZeneca outside Europe (Ex-Japan & other Asian countries) where Kyowa Kirin hold the rights
  • Brodalumab (marketed as Kyntheum in the EU) is a mAb targeting IL-17 receptor A (IL17R) and has received EMA’s MAA in Jul’2017- currently indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy

Click here to­ read full press release/ article | Ref: Business Wire | Image: PharmaStar


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions